These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26838582)

  • 21. Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial.
    van Halewijn KF; Bohnen AM; van den Berg PJ; Pasmans SGMA; Bindels PJE; Elshout G
    BMJ Open; 2019 Jun; 9(6):e027239. PubMed ID: 31221882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use.
    Sheary B
    Dermatitis; 2018; 29(4):213-218. PubMed ID: 29923852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with steroid phobia in caregivers of children with atopic dermatitis.
    Kojima R; Fujiwara T; Matsuda A; Narita M; Matsubara O; Nonoyama S; Ohya Y; Saito H; Matsumoto K
    Pediatr Dermatol; 2013; 30(1):29-35. PubMed ID: 22747965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey.
    Takahashi-Ando N; Jones MA; Fujisawa S; Hama R
    Drug Healthc Patient Saf; 2015; 7():57-62. PubMed ID: 25897263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salivary cortisol response to stress in young children with atopic dermatitis.
    Kojima R; Matsuda A; Nomura I; Matsubara O; Nonoyama S; Ohya Y; Saito H; Matsumoto K
    Pediatr Dermatol; 2013; 30(1):17-22. PubMed ID: 22612522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid use.
    Smith SD; Farrugia LL; Harris V; Lee A; Carter SR; Blaszczynski A; Fischer G
    J Dermatolog Treat; 2017 Nov; 28(7):642-646. PubMed ID: 28349719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adrenal function following topical steroid treatment in children with atopic dermatitis.
    Patel L; Clayton PE; Addison GM; Price DA; David TJ
    Br J Dermatol; 1995 Jun; 132(6):950-5. PubMed ID: 7662574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
    Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
    J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey.
    El Hachem M; Gesualdo F; Ricci G; Diociaiuti A; Giraldi L; Ametrano O; Occella C; Fortina AB; Milioto M; Arcangeli F; Simonetti O; Giancristoforo S; Calamelli E; Mazzatenta C; Neri I
    Ital J Pediatr; 2017 Feb; 43(1):22. PubMed ID: 28245844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation.
    Kawakami T; Soma Y; Morita E; Koro O; Yamamoto S; Nakamura K; Tamaki K; Yajima K; Imaizumi A; Matsunaga R; Murakami N; Kashima M; Mizoguchi M
    Dermatology; 2001; 203(1):32-7. PubMed ID: 11549797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study.
    Rossi AB; Bacquey A; Nocera T; Thouvenin MD
    Dermatol Ther (Heidelb); 2018 Jun; 8(2):217-228. PubMed ID: 29511936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of patchy parakeratosis in normal-appearing skin in patients with active atopic dermatitis and in patients with healed atopic dermatitis: a cause of impaired barrier function of the atopic skin.
    Sakurai K; Sugiura H; Matsumoto M; Uehara M
    J Dermatol Sci; 2002 Oct; 30(1):37-42. PubMed ID: 12354418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    El-Batawy MM; Bosseila MA; Mashaly HM; Hafez VS
    J Dermatol Sci; 2009 May; 54(2):76-87. PubMed ID: 19303745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory activity of CX-659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses.
    Inoue Y; Isobe M; Shiohara T; Hayashi H
    Int Arch Allergy Immunol; 2003 Jun; 131(2):143-52. PubMed ID: 12811023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical corticosteroid phobia among caretakers of children with atopic dermatitis: A cross-sectional study using TOPICOP in Japan.
    Saito-Abe M; Futamura M; Yamamoto-Hanada K; Yang L; Suzuki K; Ohya Y
    Pediatr Dermatol; 2019 May; 36(3):311-316. PubMed ID: 30882946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis.
    Gonzalez ME; Schaffer JV; Orlow SJ; Gao Z; Li H; Alekseyenko AV; Blaser MJ
    J Am Acad Dermatol; 2016 Sep; 75(3):481-493.e8. PubMed ID: 27543211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis.
    Ellison JA; Patel L; Ray DW; David TJ; Clayton PE
    Pediatrics; 2000 Apr; 105(4 Pt 1):794-9. PubMed ID: 10742322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.
    Brunner PM; Khattri S; Garcet S; Finney R; Oliva M; Dutt R; Fuentes-Duculan J; Zheng X; Li X; Bonifacio KM; Kunjravia N; Coats I; Cueto I; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol; 2016 Jul; 138(1):169-178. PubMed ID: 26948076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.